PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of geronaLink to Publisher's site
 
J Gerontol A Biol Sci Med Sci. 2016 May; 71(5): 571–577.
Published online 2015 May 4. doi:  10.1093/gerona/glv046
PMCID: PMC5007735
Editor's choice

Adverse Geriatric Outcomes Secondary to Polypharmacy in a Mouse Model: The Influence of Aging

Abstract

We aimed to develop a mouse model of polypharmacy, primarily to establish whether short-term exposure to polypharmacy causes adverse geriatric outcomes. We also investigated whether old age increased susceptibility to any adverse geriatric outcomes of polypharmacy. Young (n = 10) and old (n = 21) male C57BL/6 mice were administered control diet or polypharmacy diet containing therapeutic doses of five commonly used medicines (simvastatin, metoprolol, omeprazole, acetaminophen, and citalopram). Mice were assessed before and after the 2- to 4-week intervention. Over the intervention period, we observed no mortality and no change in food intake, body weight, or serum biochemistry in any age or treatment group. In old mice, polypharmacy caused significant declines in locomotor activity (pre minus postintervention values in control 2±13 counts, polypharmacy 32±7 counts, p < .05) and front paw wire holding impulse (control −2.45±1.02 N s, polypharmacy +1.99±1.19 N s, p < .05), loss of improvement in rotarod latency (control −59±11 s, polypharmacy −1.7±17 s, p < .05), and lowered blood pressure (control −0.2±3 mmHg, polypharmacy 11±4 mmHg, p < .05). In young mice, changes in outcomes over the intervention period did not differ between control and polypharmacy groups. This novel model of polypharmacy is feasible. Even short-term polypharmacy impairs mobility, balance, and strength in old male mice.

Polypharmacy (use of five or more different medicines) is prevalent in older adults (1,2). In population-based studies, 52% of people older than 80 years in Scotland (2) and 66% of those aged older than 75 years in Australia (3) use five or more medicines, and in nursing homes in the United States, 40% of residents use nine or more medicines (4). This is a consequence of the increase in multimorbidity with aging, for which multiple medicines may be prescribed (2,5). In observational studies, polypharmacy is associated with increased risks of adverse outcomes and geriatric syndromes in older people including hospitalization, institutionalization, falls, incontinence, cognitive impairment, and even death (6). In a population of Australian community-dwelling older men, we found that polypharmacy at baseline more than doubled the risk of incident frailty after 2 years (7). Some studies suggest that these associations are due to confounding by the indications for the medicines (8,9). Others suggest that the type of medicines rather than the number of medicines drives the association with adverse outcomes such as falls, functional impairment, and frailty (7,10,11). As the number of medicines taken increases, the risk of both predictable and unpredictable adverse outcomes increases combinatorially.

Not only are older adults at increased risk of receiving polypharmacy, but the biophysiological changes of old age alter susceptibility to the effects of medicines (12–14). Changes in body composition and hepatic and renal clearance impact on pharmacokinetics, increasing exposure to most drugs and altering the metabolites formed, with impacts on toxicity (13). For example, in old age, changes in drug disposition and metabolism of acetaminophen result in less hepatotoxicity and more nephrotoxicity (15–17). Age-related changes in specific receptors as well as changes in physiological reserve affect pharmacodynamics (18). Polypharmacy, especially given these age-dependent changes in pharmacokinetics and pharmacodynamics, dramatically increases the risk of drug interactions (19), yet most drug interaction studies focus only on two medicines. Therefore it remains uncertain whether polypharmacy per se is harmful, and if polypharmacy is harmful, what the size of that harm might be in different age groups.

It is not ethical or feasible to use randomized controlled trials to rigorously test the effects of multiple concurrent medicines on geriatric outcomes in highly heterogeneous populations of older people. Observational studies are limited by the wide range of exposures to different combinations of medicines and doses, by residual confounding by different types and severity of comorbidities, and by confounding by environmental factors like diet and exercise (20).

Mouse studies are a routine part of the preclinical testing of the toxicity of individual medicines where the risk and degree of harm of a medicine can be ascertained in the absence of underlying disease. This type of approach could also be utilized to investigate the causality and mechanisms for the association between polypharmacy and adverse geriatric outcomes: frailty, physical and cognitive function, and survival. Preclinical testing of polypharmacy is now possible with the development of animal models of geriatric outcomes, for example, a Mouse Clinical Frailty Index that is comparable to the Frailty Index in humans (21–23) can be used to assess frailty; locomotor activity in an open field is used to measure physical activity; the rotarod test is used to measure gait speed and falls risk (24); and a front paw wire hang is used as a surrogate test for grip strength (25). We recently evaluated the effects of a range of anti-aging interventions, including the drug resveratrol, on Mouse Clinical Frailty Index in aging mice (26). The other tests of physical function have been used to evaluate the effects of some single drugs in toxicity studies in young animals (eg (27–29)), and in longevity studies in aged animals (30,31). To our knowledge, there are no previous animal studies evaluating the effects of polypharmacy on geriatric outcomes.

We aimed primarily to develop a mouse model of polypharmacy and to establish whether short-term exposure to polypharmacy causes adverse geriatric outcomes in young or in old mice. Our secondary aim was to investigate whether old age increased susceptibility to any adverse geriatric outcomes caused by polypharmacy.

Methods

Animals

The polypharmacy model was established in young (14.1±0.0 weeks, n = 10) and old (99.2±0.2 weeks, n = 21) C57BL/6 male mice. This strain is standard in drug development, preclinical toxicology (32), and in studies on ageing (25) and was also used to validate the Mouse Clinical Frailty Index (22). Healthy C57BL/6 male mice were obtained from and housed at the Kearns Facility, Kolling Institute of Medical Research, Sydney, Australia. Animals were maintained on a 12-h light–dark cycle, housed in boxes of up to four (separated if fighting), given cardboard rolls for stimulation, and had ad libitum access to food (23% protein, 6% fat, 5% fiber, Rat and Mouse Premium Breeder Diet, Gordon’s Specialty Stockfeeds, Yanderra, NSW, Australia) and water. The study was approved by the Northern Sydney Local Health District Animal Care Ethics Committee, Sydney, Australia.

Drug Regimens

The medicines for the polypharmacy regimen were selected based on drug classes most commonly used by older Australians (3), which are not likely to be toxic when given alone to a healthy mouse based on previous animal studies (27–30,33,34), have similar pharmacokinetics and pharmacodynamics in mice and humans (35–39), and are not routinely dose-adjusted in old age (40). Many different combinations of medicines are seen in clinical practice and these exposures represent common treatments of common comorbidities in older people. Doses were taken from previous studies of long-term administration of these medicines as monotherapy to mice, based on an anticipated food intake of 0.18±0.05g food/g mouse/day (41).

Based on the above-mentioned principles, the polypharmacy regimen we designed was a lipid-lowering agent for prevention and treatment of cardiovascular disease (simvastatin 20mg/kg/day) (30), a beta blocker for prevention and treatment of cardiovascular disease (metoprolol 350mg/kg/day) (42), a proton pump inhibitor for treatment of gastroesophageal reflux disease (omeprazole 10mg/kg/day) (33), a simple analgesic (acetaminophen 100mg/kg/day) (43), and a selective serotonin reuptake inhibitor antidepressant (citalopram 10mg/kg/day) (44). Studies of pathology of aged C57BL/6 mice (45) suggest that the cohort of mice in this study was unlikely to have conditions that would benefit from these medicines. Control feeds and feeds containing all five drugs (polypharmacy) contained 20% protein, 4.8% fat, and 59.4% carbohydrate (Standard Meat Free Mouse and Rat Feed, Specialty Feeds, Western Australia, Australia) and were manufactured by Specialty Feeds to our specifications. First, all mice were administered control feed for at least 2 weeks. At the end of this period, baseline assessments were performed. Then mice were administered control feed or polypharmacy feed containing five drugs for 2 weeks to achieve steady state. Young mice were randomly assigned to treatment groups. Old mice were stratified by Mouse Clinical Frailty Index (22) at baseline to ensure similar frailty in each treatment group.

Assessment

Three times a week for each cage, food and mice were weighed and fresh food was given. Food intake (g food/g mouse/day) was calculated. Throughout treatment, mice were observed as per Animal Care Ethics Committee guidelines for signs of distress and for survival.

At baseline and after 12 and 14 days of treatment (for young and old cohorts respectively), mice were assessed for body weight, blood pressure, and physical function. Old mice were also assessed using the Mouse Clinical Frailty Index (22) by an assessor blinded to their treatment group. Mice were maintained on the assigned diet throughout the postdrug testing period, which lasted up to 2 weeks. Upon completion of testing, mice were euthanized (using ketamine and xylazine) and blood samples were taken. Serum liver function tests, creatinine, albumin, and calcium were measured using an Abbott Architect Clinical Chemistry Analyzer by a National Association of Testing Authorities–accredited hospital laboratory, PaLMS (Pacific Laboratory Medicine Services) at Royal North Shore Hospital (Sydney, Australia).

Blood pressure was measured by the tail cuff method using the CODA Non-invasive Blood Pressure System (Kent Scientific Corporation, CT, USA). Measurements were always carried out at the same time of the 12-h light cycle.

For rotarod latency, a measure of motor performance, all experiments were done under white light and mice were acclimatized to the room for 30min before testing. The rotarod device gradually accelerated from 4 to 40rpm over 300 s (Ugo Basile, Varese, Italy). Each test session consisted of three trials with a 30-min rest period between each trial. The first and second trials included a habituation phase for 60 and 20 s, respectively, during which the drum rotated at a fixed speed of 4rpm. In the test phase, the latency to fall was recorded for each animal. Rotarod latency for each mouse was calculated as the average of three trials, consistent with other studies of health span in aging mice (46).

Front paw wire hang experiments, measures of forelimb strength, were performed toward the end of the 12-h light cycle under white light. Each mouse was weighed prior to testing. Mice were acclimatized to the room for 30min before testing. The apparatus consisted of a single 1mm in diameter wire mounted at a height of 37cm between two posts situated 75cm apart. Soft padding was placed on the base to cushion the fall of the mouse. To place the mouse on the wire, the animal was raised by its tail above the wire and then slowly lowered until it grasped the wire at the center of the apparatus with both front paws. The body was then slowly lowered below the wire and released (47). Each test session consisted of three trials with a 30-min rest period between each trial. The latency to fall for each mouse was calculated as the average of three trials. Front paw holding impulse (N s) was calculated by: mouse weight (grams) x latency to fall (s) x 0.00980665 (gravitational force, N/g) (48).

Spontaneous locomotion was measured using the open field test. Testing was carried out under red light at the end of the 12-h light phase. Mice were acclimatized to the room for 30min before testing. Each animal was placed in the middle of an open topped, perspex enclosure (50 x 50 x 50cm) and activity was recorded with a camera situated above the arena (49). Activity of young mice was evaluated for 2min and old mice, which are less ambulant, were assessed for 5min, consistent with previous studies (50). The floor and walls of the arena were cleaned with 70% ethanol between each mouse. For analysis, the floor area was divided into a 4 x 4 grid (12 peripheral and four central squares) and the number of line crossings by the hind paws was counted. The number of times that a mouse reared up on its hind legs (on- and off-wall) was also counted. Locomotor activity of each mouse was assessed by the sum of line crossings and rearings (49).

The Mouse Clinical Frailty Index, as developed by Whitehead and colleagues (22) is a simple, noninvasive clinical assessment method for the quantification of frailty. It takes into consideration 31 parameters to give an overall score of frailty. In our study, frailty testing was carried out on old mice by an experienced, trained observer (AK). Old mice were allocated to each test group (control or polypharmacy) based on their baseline Frailty Index, with each group having a similar mean Frailty Index and a similar range of Frailty Indices at baseline.

Analysis

The study was powered to detect a significant difference in locomotor performance and rotarod latency in old mice after treatment with polypharmacy compared to control. We estimated that the size of a clinically relevant negative effect from polypharmacy would be similar to that of the positive effects on health span seen with metformin (31). If the variability was similar to this study, we would require a sample size of five per group to detect a difference of 0.008 m min-1 in locomotor performance and a difference of 30 s in rotarod latency with power of 80% and alpha of 0.05. In view of the greater interindividual variability in pharmacology of multiple drugs in old age, we estimated a sample size of 12 for the old animals treated with polypharmacy to detect a clinically relevant difference.

The change in each outcome over the intervention period was measured for each animal. The mean change in each outcome was calculated for each age and treatment group. To investigate the primary aim, whether polypharmacy affected geriatric outcomes in old or in young mice, the mean change in each outcome was compared between old control and old polypharmacy-treated mice and between young control and young polypharmacy-treated mice using the Student’s t test. To determine the relative susceptibility of young and old mice, the change in each outcome over the study period was compared between both age and treatment groups using two-way ANOVA to measure the significance of the interaction between age and treatment. Open field results were normalized to 2min for both age groups for this two-way ANOVA. To further describe the outcome data, descriptive statistics were used to characterize the mean values for each age and treatment group, before and after treatment. A two-way mixed ANOVA analysis was used to determine the effect of time (within-subjects factor) and treatment (between subjects factor), within each age group. To determine the effect of age on outcomes pre- and post-treatments, a three-way mixed ANOVA was used to measure the significance of the interaction between age, treatment, and time. Open field results were normalized to 2min for both age groups for the three-way mixed ANOVA. All data are presented as mean ± standard error of the mean.

Results

The polypharmacy regimen was tolerated by young and old mice, with no change in food intake or body weight, and no mortality observed over the study period for any age or treatment group (Table 1). Serum liver function tests, creatinine, and calcium were not significantly affected by the medication regimens. Mice in all groups consumed the lower end of the range of food anticipated, resulting in mean doses of approximately simvastatin 14mg/kg/day, metoprolol 245mg/kg/day, omeprazole 7mg/kg/day, acetaminophen 70mg/kg/day, and citalopram 7mg/kg/day.

Table 1.
Characteristics of young and old mice administered control and polypharmacy diets.

The change in outcome with treatment was calculated for each mouse and averaged within each age and treatment group to describe the effects of polypharmacy compared to control diet (Figure 1). Among old mice, compared to those treated with control diet, those treated with polypharmacy had a significantly greater impairment in performance on locomotor activity (Figure 1A), rotarod latency (Figure 1C), and front paw wire holding impulse (Figure 1E); no significant difference in change in Mouse Clinical Frailty Index (Figure 1I); and a significantly greater drop in blood pressure (Figure 1G). For young mice, the change in all outcomes over the treatment period did not differ between those receiving the control and polypharmacy treatments (Figure 1B, ,D,D, ,F,F, ,H).H). On two-way ANOVA, there was no statistically significant interaction between age and treatment for any outcome.

Figure 1.
Change in outcomes from baseline to after the intervention period with control or polypharmacy diet in old and young male C57BL/6 mice. (A) Locomotor activity old; (B) locomotor activity young; (C) rotarod latency old; (D) rotarod latency young; (E) front ...

Figure 2 shows the mean results for locomotor activity, rotarod latency, and front paw wire holding impulse in each age and treatment group. Two-way mixed ANOVA analysis showed no significant interaction between time and treatment group for any outcome in the young mice (Figure 2A). In old mice, there was a significant interaction between time and treatment for mean front paw wire holding impulse (F[1,19] = 6.6, p = .019), rotarod latency (F[1,19] = 6.1, p = .023), mean locomotor activity in the open field (F[1,19] = 4.6, p = .045), but not mean Mouse Clinical Frailty Index. Plotting the mean values showed that in old mice polypharmacy reduced mean locomotor activity in the open field, but mean rotarod latency and mean front paw wire holding impulse increased over the study period in the old controls but not in the old polypharmacy group (Figure 2B). Over the intervention period, mean Mouse Clinical Frailty Index did not change significantly in the old control group (0.19±0.03 pre, 0.18±0.03 post) or in the old polypharmacy group (0.16±0.01 pre, 0.18±0.01 post). On three-way mixed ANOVA, there was no statistically significant interaction between time, age, and treatment for any outcome.

Figure 2.
Mean values for functional outcomes before and after the intervention with control diet or polypharmacy diet in (A) young and (B) old male C57BL/6 mice. Locomotor activity was performed for 2min in young mice and 5min in old mice. Values for rotarod latency ...

Discussion

In this study, we developed a mouse model of polypharmacy to establish whether short-term exposure to polypharmacy causes adverse geriatric outcomes. The polypharmacy regimen for the intervention period was tolerated by young and old mice, without standard signs of toxicity such as mortality or abnormal serum measures of hepatic or renal function (Table 1). In old mice, 2–4 weeks of polypharmacy resulted in significant declines in locomotor activity, rotarod latency, and front paw wire holding impulse, as well as lower blood pressure (Figure 1). In young mice, outcomes were not significantly affected by polypharmacy, with similar changes in outcomes observed in the control and polypharmacy groups over the treatment period (Figure 1). In this small sample, there was no statistically significant interaction between age and treatment on geriatric outcomes.

To our knowledge, none of the drugs in the polypharmacy regimen has been shown to impair functional outcomes when used as monotherapy at the administered doses in rodents, although there is limited data from old mice. Lifelong simvastatin has been shown to have no effect on functional outcomes in mice (30). Acetaminophen at doses from 25 to 300mg/kg has no effect on rotarod performance in young rats with neuropathic pain (29) and its effects on function in old rodents are unknown. Metoprolol administered for 28 days to young rats does not result in central nervous system depression at doses from 300 to 750mg/kg, but does cause mild depression at 1000mg/kg, which is four times higher than the dose used in the polypharmacy diet (28), with no reports of its effects in old mice. In young mice, citalopram does not affect rotarod performance at the 10-mg/kg dose used in our polypharmacy regimen (27), but does impair performance on the rotarod at a much higher dose (100mg/kg) (27), and its effects on physical function have not been evaluated in old mice. The effects of omeprazole on physical function in rodents are not well documented in any age group. The results of this study demonstrate clearly that polypharmacy with drug doses previously shown to have no effect on performance individually in young mice impairs physical function in old but not in young mice.

The strengths of this study are the selection of clinically relevant treatment regimens and rigorous collection of validated outcomes that are standard to studies of pharmacology, toxicology, and aging (22,25,32). The geriatric outcomes can be translated to comparable measures in humans (22,25). Furthermore, the physical impairments seen with polypharmacy in old mice are consistent with results of observational studies in older adults (6), such as the association of polypharmacy with reduced 6-min walk distance (51) and impaired balance (52).

Further studies should assess both pharmacokinetic and pharmacodynamic factors to determine the mechanisms of the observed effects of polypharmacy on functional outcomes in old age. It is possible that the intervention period (2 weeks) may have been too short in order to observe the full effects of drug therapy on outcomes. The Mouse Clinical Frailty Index (22) contains many items that may take longer than 2–4 weeks to change, such as those relating to the integument and musculoskeletal systems. Larger studies may be required to more precisely describe the effects of polypharmacy and to determine whether there is a significant interaction between age and treatment effect. Although we did not detect an interaction between age and treatment, if these studies had only been performed on young and not on old animals, it would have appeared that there was no effect of polypharmacy on geriatric outcomes. This finding supports the need to study exposures of the medicines that are used in older people in old animals (14). Future experiments should also investigate the effects of polypharmacy in middle age (12 months) as well as in the very old (30 months) to determine changes in susceptibility through the lifespan (53). Studies of long-term treatment from middle to old age will be better able to determine the functional risk of chronic polypharmacy in old age.

Future studies are needed to investigate the generalizability of this study. The results reported here may be specific to the medicines selected. Further studies are required to elicit the effects of polypharmacy regimens containing varying classes and doses of medicines. Although our results are consistent with those of observational studies in male and female older adults, our experiments used only male C57BL/6 mice. Studies in different sexes, strains, and species may differ due to strain and species differences in pharmacology in old age (32,54) and in aging itself (53,55).

In humans, it is important to evaluate the risks of a medication against the potential benefits of therapy, on geriatric and other outcomes. This assessment is complicated by multiple factors such as age, sex, multimorbidity, and polypharmacy. In this study, we present a model for polypharmacy in healthy young and old mice. The toxicological information gained from studies in healthy animals provides valuable translational data to inform clinicians of the nature and magnitude of the impairments in geriatric outcomes caused by polypharmacy.

In conclusion, in this study we present a novel model of polypharmacy, which is feasible and shows that short-term treatment significantly impairs mobility, balance, and strength in old C57BL/6 male mice. This preclinical model can be used to inform clinicians of the adverse effects of polypharmacy and to test the effects of new medicines on geriatric and other outcomes in the setting of polypharmacy, which is the condition under which medicines are commonly used in older adults.

Funding

This study was funded by the Penney Ageing Research Unit, Royal North Shore Hospital, Australia. Rafael de Cabo and Sarah Mitchell are supported by the National Institute on Aging, National Institutes of Health.

Conflicts of Interest

The authors do not have any conflicts of interest relevant to this paper.

Acknowlegments

We thank Dr. Chris Vaughn for advice and assistance in measurement of the rotarod latency and locomotor activity in open field and Ms. Jillian Patterson for providing statistical advice.

References

1. Qato DM, Alexander GC, Conti RM, Johnson M, Schumm P, Lindau ST. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA. 2008;300:2867–2878. doi:10.1001/jama.2008.892 [PMC free article] [PubMed]
2. Payne RA, Avery AJ, Duerden M, Saunders CL, Simpson CR, Abel GA. Prevalence of polypharmacy in a Scottish primary care population. Eur J Clin Pharmacol. 2014;70:575–581. doi:10.1007/s00228-013-1639-9 [PubMed]
3. Morgan TK, Williamson M, Pirotta M, Stewart K, Myers SP, Barnes J. A national census of medicines use: a 24-hour snapshot of Australians aged 50 years and older. Med J Aust. 2012;196:50–53. doi:10.5694/mja11.10698 [PubMed]
4. Dwyer LL, Han B, Woodwell DA, Rechtsteiner EA. Polypharmacy in nursing home residents in the United States: results of the 2004 National Nursing Home Survey. Am J Geriatr Pharmacother. 2010;8:63–72. doi:10.1016/j.amjopharm.2010.01.001 [PubMed]
5. Guiding Principles for the Care of Older Adults With Multimorbidity: An Approach for Clinicians. Guiding Principles for the Care of Older Adults With Multimorbidity: An Approach for Clinicians: American Geriatrics Society Expert Panel on the Care of Older Adults with Multimorbidity. J Am Geriatr Soc. 2012;60:E1–E25. doi:10.1111/j.1532-5415.2012.04188.x [PMC free article] [PubMed]
6. Hilmer SN, Gnjidic D. The effects of polypharmacy in older adults. Clin Pharmacol Ther. 2009;85:86–88. doi:10.1038/clpt.2008.224 [PubMed]
7. Gnjidic D, Hilmer SN, Blyth FM, et al. High-risk prescribing and incidence of frailty among older community-dwelling men. Clin Pharmacol Ther. 2012;91:521–528. doi:10.1186/1471-2458-13-115 [PubMed]
8. Lawlor DA, Patel R, Ebrahim S. Association between falls in elderly women and chronic diseases and drug use: cross sectional study. BMJ. 2003;327:712–717. doi:10.1136/bmj.327.7417.712 [PMC free article] [PubMed]
9. Payne RA, Abel GA, Avery AJ, Mercer SW, Roland MO. Is polypharmacy always hazardous? A retrospective cohort analysis using linked electronic health records from primary and secondary care. Br J Clin Pharmacol. 2014;77:1073–1082. doi:10.1111/bcp.12292 [PMC free article] [PubMed]
10. Ziere G, Dieleman JP, Hofman A, Pols HA, van der Cammen TJ, Stricker BH. Polypharmacy and falls in the middle age and elderly population. Br J Clin Pharmacol. 2006;61:218–223. doi:10.1111/j.1365-2125.2005.02543.x [PMC free article] [PubMed]
11. Hilmer SN, Mager DE, Simonsick EM, et al. A drug burden index to define the functional burden of medications in older people. Arch Intern Med. 2007;167:781–787. doi:10.1001/archinte.167.8.781 [PubMed]
12. Hilmer SN, McLachlan AJ, Le Couteur DG. Clinical pharmacology in the geriatric patient. Fundam Clin Pharmacol. 2007;21:217–230. doi:10.1111/j.1472-8206.2007.00473.x [PubMed]
13. McLean AJ, Le Couteur DG. Aging biology and geriatric clinical pharmacology. Pharmacol Rev. 2004;56:163–184. doi:10.1124/pr.56.2.4 [PubMed]
14. Kennedy BK, Berger SL, Brunet A, et al. Geroscience: linking aging to chronic disease. Cell. 2014;159:709–713. doi:10.1016/j.cell.2014.10.039 [PMC free article] [PubMed]
15. Mitchell SJ, Huizer-Pajkos A, Cogger VC, et al. Age-related pseudocapillarization of the liver sinusoidal endothelium impairs the hepatic clearance of acetaminophen in rats. J Gerontol A Biol Sci Med Sci. 2011;66:400–408. doi:10.1093/gerona/glq221 [PMC free article] [PubMed]
16. Mach J, Huizer-Pajkos A, Cogger VC, et al. The effect of aging on acetaminophen pharmacokinetics, toxicity and Nrf2 in Fischer 344 rats. J Gerontol A Biol Sci Med Sci. 2014;69:387–397. doi:10.1093/gerona/glt095 [PubMed]
17. Beierschmitt WP, Keenan KP, Weiner M. The development of acetaminophen-induced nephrotoxicity in male Fischer 344 rats of different ages. Arch Toxicol. 1986;59:206–210. [PubMed]
18. Bowie MW, Slattum PW. Pharmacodynamics in older adults: a review. Am J Geriatr Pharmacother. 2007;5:263–303. doi:10.1016/j.amjopharm.2007.10.001 [PubMed]
19. Johnell K, Klarin I. The relationship between number of drugs and potential drug-drug interactions in the elderly: a study of over 600,000 elderly patients from the Swedish Prescribed Drug Register. Drug Saf. 2007;30:911–918. doi:0114-5916/07/0010-0911/$44.95/0 [PubMed]
20. Hilmer SN, Gnjidic D, Abernethy DR. Pharmacoepidemiology in the postmarketing assessment of the safety and efficacy of drugs in older adults. J Gerontol A Biol Sci Med Sci. 2012;67:181–188. doi:10.1093/gerona/glr066 [PubMed]
21. Howlett SE, Rockwood K. Ageing: Develop models of frailty. Nature. 2014;512:253. doi:10.1038/512253d [PubMed]
22. Whitehead JC, Hildebrand BA, Sun M, et al. A clinical frailty index in aging mice: comparisons with frailty index data in humans. J Gerontol A Biol Sci Med Sci. 2014;69:621–632. doi:10.1093/gerona/glt136 [PMC free article] [PubMed]
23. Feridooni HA, Sun MH, Rockwood K, Howlett SE. Reliability of a Frailty Index based on the clinical assessment of health deficits in male C57BL/6J mice. J Gerontol A Biol Sci Med Sci. 2014. Sep 9. doi:10.1093/gerona/glu161 [PMC free article] [PubMed]
24. Ingram DK, Reynolds MA. Assessing the predictive validity of psychomotor tests as measures of biological age in mice. Exp Aging Res. 1986;12:155–162. doi:10.1080/03610738608259454 [PubMed]
25. Graber TG, Ferguson-Stegall L, Kim JH, Thompson LV. C57BL/6 neuromuscular healthspan scoring system. J Gerontol A Biol Sci Med Sci. 2013;68:1326–1336. doi:10.1093/gerona/glt032 [PMC free article] [PubMed]
26. Kane A, Hilmer SN, Boyer D, Gavin K, Nines D, Howlett SE, et al. Impact of longevity interventions on a validated mouse clinical frailty index. J Geront Biol Sci Med Sci. 2015 Feb 22. pii: glu315. [Epub ahead of print]. [PMC free article] [PubMed]
27. Strömberg C. Interactions of antidepressants and ethanol on spontaneous locomotor activity and rotarod performance in NMRI and C57BL/6 mice. J Psychopharmacol. 1988;2:61–66. doi:10.1177/026988118800200201 [PubMed]
28. Deore MD, Dadarkar SS, Bakre DG, Gatne MM. Toxicity studies of metoprolol succinate after repeated oral exposure in albino rats. Toxicol Int. 2005;12:101–107.
29. Im KS, Jung HJ, Kim JB, et al. The antinociceptive effect of acetaminophen in a rat model of neuropathic pain. Kaohsiung J Med Sci. 2012;28:251–258. doi:10.1016/j.kjms.2011.11.003 [PubMed]
30. Miller RA, Harrison DE, Astle CM, et al. Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. J Gerontol A Biol Sci Med Sci. 2011;66:191–201. doi:10.1093/gerona/glq178 [PMC free article] [PubMed]
31. Martin-Montalvo A, Mercken EM, Mitchell SJ, et al. Metformin improves healthspan and lifespan in mice. Nat Commun. 2013;4:2192. doi:10.1038/ncomms3192 [PMC free article] [PubMed]
32. Muruganandan S, Sinal CJ. Mice as clinically relevant models for the study of cytochrome P450-dependent metabolism. Clin Pharmacol Ther. 2008;83:818–828. doi:10.1038/clpt.2008.50 [PubMed]
33. Tallman MN, Ali SY, Smith PC. Altered pharmacokinetics of omeprazole in cystic fibrosis knockout mice relative to wild-type mice. Drug Metab Dispos. 2004;32:902–905. [PubMed]
34. McGill MR, Sharpe MR, Williams CD, Taha M, Curry SC, Jaeschke H. The mechanism underlying acetaminophen-induced hepatotoxicity in humans and mice involves mitochondrial damage and nuclear DNA fragmentation. J Clin Invest. 2012;122:1574–1583. doi:10.1172/JCI59755 [PMC free article] [PubMed]
35. Vickers S, Duncan CA, Vyas KP, et al. In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase. Drug Metab Dispos. 1990;18:476–483. [PubMed]
36. Ablad B, Borg KO, Carlsson E, et al. A survey of the pharmacological properties of metoprolol in animals and man. Acta Pharmacol Toxicol (Copenh). 1975;36(Suppl 5):7–23. doi:10.1111/j.1600-0773.1975.tb03318.x [PubMed]
37. Regårdh CG, Gabrielsson M, Hoffman KJ, Löfberg I, Skånberg I. Pharmacokinetics and metabolism of omeprazole in animals and man–an overview. Scand J Gastroenterol Suppl. 1985;108:79–94. [PubMed]
38. Crowley JJ, Blendy JA, Lucki I. Strain-dependent antidepressant-like effects of citalopram in the mouse tail suspension test. Psychopharmacology (Berl). 2005;183:257–264. doi:10.1007/s00213-005-0166-5 [PubMed]
39. Birge RB, Bartolone JB, Hart SG, et al. Acetaminophen hepatotoxicity: correspondence of selective protein arylation in human and mouse liver in vitro, in culture, and in vivo. Toxicol Appl Pharmacol. 1990;105:472–482. [PubMed]
40. MIMS annual. St Leonards, Australia: UBM Medica Australia; 2013.
41. Bachmanov AA, Reed DR, Beauchamp GK, Tordoff MG. Food intake, water intake, and drinking spout side preference of 28 mouse strains. Behav Genet. 2002;32:435–443. [PMC free article] [PubMed]
42. Harding VB, Jones LR, Lefkowitz RJ, Koch WJ, Rockman HA. Cardiac beta ARK1 inhibition prolongs survival and augments beta blocker therapy in a mouse model of severe heart failure. Proc Natl Acad Sci U S A. 2001;98:5809–5814. doi:10.1073/pnas.091102398 [PubMed]
43. Mallet C, Barrière DA, Ermund A, et al. TRPV1 in brain is involved in acetaminophen-induced antinociception. PLoS One. 2010;5 :pii:e12748. doi:10.1371/journal.pone.0012748 [PMC free article] [PubMed]
44. Abid S, Houssaini A, Chevarin C, et al. Inhibition of gut- and lung-derived serotonin attenuates pulmonary hypertension in mice. Am J Physiol Lung Cell Mol Physiol. 2012;303:L500–L508. doi:10.1152/ajplung.00049.2012 [PubMed]
45. Pettan-Brewer C, Treuting PM. Practical pathology of aging mice. Pathobiol Aging Age Relat Dis. 2011;1. doi:10.3402/pba.v1i0.7202 [PMC free article] [PubMed]
46. Mitchell SJ, Martin-Montalvo A, Mercken EM, et al. The SIRT1 activator SRT1720 extends lifespan and improves health of mice fed a standard diet. Cell Rep. 2014;6:836–843. doi:10.1016/j.celrep.2014.01.031 [PMC free article] [PubMed]
47. Klein SM, Vykoukal J, Lechler P, et al. Noninvasive in vivo assessment of muscle impairment in the mdx mouse model–a comparison of two common wire hanging methods with two different results. J Neurosci Methods. 2012;203:292–297. doi:10.1016/j.jneumeth.2011.10.001 [PubMed]
48. Carlson CG, Rutter J, Bledsoe C, et al. A simple protocol for assessing inter-trial and inter-examiner reliability for two noninvasive measures of limb muscle strength. J Neurosci Methods. 2010;186:226–230. doi:10.1016/j.jneumeth.2009.11.006 [PubMed]
49. Walsh RN, Cummins RA. The Open-Field Test: a critical review. Psychol Bull. 1976;83:482–504. [PubMed]
50. Justice JN, Carter CS, Beck HJ, et al. Battery of behavioral tests in mice that models age-associated changes in human motor function. Age (Dordr). 2014;36:583–592. doi:10.1007/s11357-013-9589-9 [PMC free article] [PubMed]
51. Lord SR, Menz HB. Physiologic, psychologic, and health predictors of 6-minute walk performance in older people. Arch Phys Med Rehabil. 2002;83:907–911. doi:10.1053/apmr.2002.33227 [PubMed]
52. Agostini JV, Han L, Tinetti ME. The relationship between number of medications and weight loss or impaired balance in older adults. J Am Geriatr Soc. 2004;52:1719–1723. doi:10.1111/j.1532-5415.2004.52467.x [PubMed]
53. Miller RA, Nadon NL. Principles of animal use for gerontological research. J Gerontol A Biol Sci Med Sci. 2000;55:B117–B123. doi:10.1093/gerona/55.3.B117 [PubMed]
54. Schwartz JB. The current state of knowledge on age, sex, and their interactions on clinical pharmacology. Clin Pharmacol Ther. 2007;82:87–96. doi:10.1038/sj.clpt.6100226 [PubMed]
55. Ali SS, Xiong C, Lucero J, Behrens MM, Dugan LL, Quick KL. Gender differences in free radical homeostasis during aging: shorter-lived female C57BL6 mice have increased oxidative stress. Aging Cell. 2006;5:565–574. doi:10.1111/j.1474-9726.2006.00252.x [PubMed]

Articles from The Journals of Gerontology Series A: Biological Sciences and Medical Sciences are provided here courtesy of Oxford University Press